Evidence map›Paper›PMID 29395976›Full record

ArticleBioorganic & medicinal chemistry letters2018

Screening one bead one compound libraries against serum using a flow cytometer: Determination of the minimum antibody concentration required for ligand discovery.

Osayemwenre Erharuyi, Scott Simanski, Patrick J McEnaney, Thomas Kodadek

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Synthesis and Screening of a DNA-Encoded Library of Non-Peptidic Macrocycles.Angewandte Chemie (International ed. in English) · 2022
    Article
  2. Article
  3. Evolving a Peptide: Library Platforms and Diversification Strategies.International journal of molecular sciences · 2019
    Review
  4. Beyond protein binding: recent advances in screening DNA-encoded libraries.Chemical communications (Cambridge, England) · 2019
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Osayemwenre ErharuyiDepartment of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.
Scott SimanskiDepartment of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.
Patrick J McEnaneyDepartment of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.
Thomas KodadekDepartment of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA. Electronic address: kodadek@scripps.edu.
Scripps Research Institute · US

Funding

Discovery of antibody biomarkers for Alzheimer’s DiseaseR21AG052813 · NIA · SCRIPPS FLORIDA · PI KODADEK, THOMAS J. · 2016 to 2017
$528k
Discovery of Potent Proteasome Agonists to Improve ProteostasisR21AG054892 · NIA · SCRIPPS FLORIDA · PI KODADEK, THOMAS J. · 2017 to 2018
$523k
NIA NIH HHS R21 AG052813NIA NIH HHS R21 AG054892
6 · The paper itself

Abstract

One bead one compound (OBOC) libraries can be screened against serum samples to identify ligands to antibodies in this mixture. In this protocol, hit beads are identified by staining with a fluorescent labeled secondary antibody. When screens are conducted against two different sets of serum, antibodies, and ligands to them, can be discovered that distinguish the two populations. The application of DNA-encoding technology to OBOC libraries has allowed the use of 10 µm beads for library preparation and screening, which pass through a standard flow cytometer, allowing the fluorescent hit beads to be separated from beads displaying non-ligands easily. An important issue in using this approach for the discovery of antibody biomarkers is its analytical sensitivity. In other words, how abundant must an IgG be to allow it to be pulled out of serum in an unbiased screen using a flow cytometer? We report here a model study in which monoclonal antibodies with known ligands of varying affinities are doped into serum. We find that for antibody ligands typical of what one isolates from an unbiased combinatorial library, the target antibody must be present at 10-50 nM. True antigens, which bind with significantly higher affinity, can detect much less abundant serum antibodies.

Indexed as

Drug DiscoveryFlow CytometryAntibodies, MonoclonalDrug Evaluation, PreclinicalHumansLigandsSmall Molecule LibrariesAntibodies, MonoclonalLigandsSmall Molecule LibrariesAntibodiesBiomarkersCombinatorial librariesFlow cytometryPeptidomimetic ligand

Identifiers

PMID29395976
PMCPMC6064678
OpenAlexW2793623670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.